Johnson & Johnson $JNJ Stock Holdings Trimmed by Wellington Management Group LLP

Key Points

• Wellington Management Group LLP reduced its stake in Johnson & Johnson by 7.0%, holding approximately $3.76 billion worth of shares, making it the firm's 21st largest investment.
• Analysts have mixed reviews on Johnson & Johnson, with nine holding, ten buying, and two strong buy ratings, while the consensus target price is currently set at $174.50.
• Johnson & Johnson recently announced a quarterly dividend of $1.30 per share, with a yield of 2.9%, as part of its ongoing commitment to return value to shareholders.

Wellington Management Group LLP lowered its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 7.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 22,645,961 shares of the company's stock after selling 1,710,611 shares during the period. Johnson & Johnson accounts for approximately 0.7% of Wellington Management Group LLP's portfolio, making the stock its 21st biggest holding. Wellington Management Group LLP owned 0.94% of Johnson & Johnson worth $3,755,606,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in JNJ. Highline Wealth Partners LLC increased its stake in shares of Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after acquiring an additional 86 shares during the last quarter. Stone House Investment Management LLC purchased a new stake in Johnson & Johnson in the first quarter valued at approximately $47,000. von Borstel & Associates Inc. purchased a new stake in Johnson & Johnson in the first quarter valued at approximately $49,000. Capital A Wealth Management LLC acquired a new position in Johnson & Johnson during the fourth quarter worth approximately $50,000. Finally, Harvest Fund Management Co. Ltd purchased a new position in Johnson & Johnson during the first quarter worth approximately $52,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Analysts Set New Price Targets

A number of research firms have recently commented on JNJ. Benchmark upgraded Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Barclays upped their price target on Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Bank of America lifted their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a research note on Thursday, July 17th. Finally, Wall Street Zen lowered Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Friday, July 18th. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $174.50.

Johnson & Johnson Stock Up 0.4%

JNJ traded up $0.7890 during trading hours on Wednesday, reaching $178.5890. 9,028,878 shares of the stock traded hands, compared to its average volume of 9,045,183. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $180.61. The company has a market cap of $430.10 billion, a price-to-earnings ratio of 19.10, a PEG ratio of 2.24 and a beta of 0.41. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The firm's fifty day simple moving average is $162.13 and its two-hundred day simple moving average is $158.73.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm's revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the prior year, the company posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's payout ratio is presently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.